Literature DB >> 10646955

Beta-adrenoceptor density in chronic infarcted myocardium: a subtype specific decrease of beta1-adrenoceptor density.

R L Anthonio1, O E Brodde, D J van Veldhuisen, E Scholtens, H J Crijns, W H van Gilst.   

Abstract

UNLABELLED: Beta-adrenoceptor density is altered in different cardiac diseases. In heart failure beta-adrenoceptor density is down regulated but in acute myocardial ischemia beta-adrenoceptor density is up regulated. In hearts with myocardial infarction total beta-adrenoceptor density is decreased shortly after myocardial infarction. AIMS AND METHODS: To investigate whether total beta-adrenoceptor number is altered in the chronic phase after myocardial infarction, and to identify the specificity of alteration, we studied male Wistar rats (n = 18) which underwent a ligation of the left coronary artery or a sham operation. Twelve weeks after coronary ligation, rats were sacrificed and hearts were excised, perfused to obtain blood-free myocardium and frozen in liquid nitrogen. Infarcted myocardium was identified visually and separated from non-infarcted myocardium. Total beta-adrenoceptor number was calculated in fmol (-)-[125I]iodocyanopindolol specifically bound/mg protein and the relative amount of beta1- and beta2-adrenoceptor density was measured by inhibition of (-)-[125I]iodocyanopindolol binding with CGP 20712 A.
RESULTS: Total beta-adrenoceptor number in infarcted myocardium was significantly decreased (25.7+/-1.4 vs. 24.9+/-2.2 vs. 20.1+/-3.2 fmol/mg protein (P=0.03) resp. Sham vs. Non-infarcted vs. Infarcted myocardium), due to a decrease of only beta1-adrenoceptor density (14.7+/-0.61 vs. 12.7+/-1.09 vs. 4.84+/-0.96 fmol/mg protein (P=0.004) resp.), whereas the beta2-adrenoceptor density and the dissociation constant (Kd) were not significantly decreased.
CONCLUSION: In the infarcted myocardium total beta-adrenoceptor density is decreased due to a decreased beta1-adrenoceptor density at 12 weeks after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646955     DOI: 10.1016/s0167-5273(99)00181-3

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Barcoding of GPCR trafficking and signaling through the various trafficking roadmaps by compartmentalized signaling networks.

Authors:  Suleiman W Bahouth; Mohammed M Nooh
Journal:  Cell Signal       Date:  2017-04-24       Impact factor: 4.315

2.  Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.

Authors:  Yukiya Nomura; Hitoshi Horimoto; Shigetoshi Mieno; Ken-ichi Nakahara; Hirohisa Okawa; Masataka Yoshida; Sasaki Shinjiro
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

3.  Relative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats.

Authors:  Jatin G Burniston; Lip-Bun Tan; David F Goldspink
Journal:  Exp Physiol       Date:  2006-09-14       Impact factor: 2.969

4.  Adverse Effects on β-Adrenergic Receptor Coupling: Ischemic Postconditioning Failed to Preserve Long-Term Cardiac Function.

Authors:  Rolf Schreckenberg; Péter Bencsik; Martin Weber; Yaser Abdallah; Csaba Csonka; Kamilla Gömöri; Krisztina Kiss; János Pálóczi; Judit Pipis; Márta Sárközy; Péter Ferdinandy; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  J Am Heart Assoc       Date:  2017-12-22       Impact factor: 5.501

5.  Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats.

Authors:  Margherita Neri; Daniela Cerretani; Anna Ida Fiaschi; Pasini Franco Laghi; Pietro Euea Lazzerini; Angela Bruna Maffione; Lucia Micheli; Giancarlo Bruni; Cristina Nencini; Giorgio Giorgi; Stefano D'Errico; Carmela Fiore; Cristoforo Pomara; Irene Riezzo; Emanuela Turillazzi; Vittorio Fineschi
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.